SRSF2 mutations are abundant in ASXL1-mutated MDS/AML patients, with a frequency of 34.4% in ASXL1-mutated AML vs. 7.8% in non-mutated AML, and 28.5% in ASXL1-mutated MDS vs. 9.7% in non-mutated MDS (cBioPortal database). This evidence concerns the gene ASXL1 and acute myeloid leukemia.